STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today provided the following statement in response to a report issued by Glass, Lewis & Co., LLC (“Glass Lewis”) related to STAAR’s pending merger with Alcon (SIX/NYSE: ALC): The STAAR Board of Directors and management team strongly disagree with the recommendation issued by Glass Lewis.